تحلیل اختیاری محصول
با اجازه شما، از تحلیلهای محدود و حریمخصوصیمحور استفاده میکنیم تا مسیرهای پژوهشی مؤثر را بشناسیم. از ردیاب تبلیغاتی یا بازپخش نشست استفاده نمیکنیم. این انتخاب را میتوانید در تنظیمات تغییر دهید. بخوانید سیاست حفظ حریم خصوصی.
CVS Health Corporation's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $119.5B | |
|---|---|---|
| Revenue (ttm) | 412.6B | |
| Net income (ttm) | 4.9B | |
| EPS (ttm) | $3.82 | |
| Shares out | 1.3B | |
| P/E (trailing) | 23.6x | |
| P/E (forward) | 10.7x | |
| Dividend | $2.66 (2.96%) | |
| Volume | 3,596,555 | |
| Beta | 0.60 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $292.11B | $322.47B | $357.78B | $372.81B | $402.07B | +8.3% |
| Gross profit | $52.12B | $54.50B | $54.43B | $51.40B | $55.36B | +1.5% |
| Operating income | $13.31B | $7.95B | $13.74B | $8.52B | $4.66B | -23.1% |
| Net income | $8.00B | $4.31B | $8.34B | $4.61B | $1.77B | -31.4% |
| EPS (diluted) | $6.02 | $3.26 | $6.47 | $3.66 | $1.39 | -30.7% |
| EBITDA | $17.53B | $12.35B | $13.74B | $13.68B | $9.86B | -13.4% |
| R&D | — | — | — | — | — | — |
| SG&A | $36.23B | $37.18B | $38.36B | $40.24B | $970.0M | -59.5% |
Recent company headlines from major financial publishers.
The Base case represents the modal expected trajectory, delivering our intrinsic Fair value of $107.29 per share. Underwriting discipline drives Health Care Benefits MBR compression, supporting steady operating margin expansion through FY2027. Robust cash flow generation funds consistent debt reduction, steadily lowering financial leverage and driving sustainable earnings expansion.
In the Bull case, Medicare Advantage repricing exceeds expectations and medical loss ratios drop rapidly below baseline underwriting targets, while Caremark captures significant biosimilar and incretin dispensing volumes. Operating margins rebound toward historical peaks, generating accelerated cash flows that enable complete debt repayment ahead of schedule and substantial share repurchases.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 7.2% | $116 | $119 | $122 | $126 | $130 |
| 7.7% | $109 | $112 | $114 | $117 | $120 |
| 8.2% | $103 | $105 | $107 | $110 | $112 |
| 8.7% | $98.1 | $99.7 | $101 | $103 | $105 |
| 9.2% | $93.6 | $95.0 | $96.4 | $98.0 | $99.7 |
Upcoming earnings date and setup when available.
رتبهای که نسخهٔ پژوهشی منتشرشدهٔ هر ماه داشت. رتبه قیمت در تاریخ تحلیل را با ارزش منصفانه مقایسه میکند و سابقهای از درستی یا نادرستی ارزیابی نیست.
| سال | دی | بهمن | اسفند | فروردین | اردیبهشت | خرداد | تیر | مرداد | شهریور | مهر | آبان | آذر |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
